ClinicalTrials.gg
CompletedNCT07042165BASTAUpdated Oct 30, 2026

Treatment of Bile Acid Diarrhoea With Atorvastatin

A Phase 4 interventional study of Atorvastatin and Placebo in Bile Acid Diarrhea and Bile Acid Malabsorption, sponsored by Asger Lund, MD. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Asger Lund, MD · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diarrhea with a site in Denmark — 1 open to participants now, 2 under way, none of them phase 3. Diarrhea · Denmark.

Enrollment
7th of 11
20 · median 36
Started
2025
the only one that year
Phase 4
2 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Asger Lund, MD

Among the 13 studies in Diarrhea with a site in Denmark, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 4, and was the 13th registered.

Diarrhea

880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 13 studies in Diarrhea with a site in Denmark is open now. Recruiting first, the newest first:

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 46 Diarrhea studies recruiting now, 21 (46%) set no upper age limit and 23 (50%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diarrhea with a site in Denmark, or all of them as a file.
02

Study summary

Bile acid diarrhoea (BAD) is a socially debilitating disease with stomach pain, high stool frequency, urgency, and faecal incontinence as the main symptoms. Studies estimate that 1-2% of the population suffers from the disease.

There is an unmet need for more treatment options in patients suffering from BAD.

The investigators hypothesise that atorvastatin treatment lowers bile acid synthesis in patients with bile acid diarrhoea. The investigators will investigate this hypothesis in the current study, BASTA, which is a Randomised, Double-Blind, Placebo-Controlled, Crossover, Proof of Concept, Investigator-Initiated, Trial.

Read the detailed description

Bile acid diarrhoea (BAD) is a socially debilitating disease with stomach pain, high stool frequency, urgency, and faecal incontinence as the main symptoms. Studies estimate that 1-2% of the population suffers from the disease.

Bile acids are synthesised from cholesterol in hepatocytes through a tightly regulated enzymatic process and then excreted to the gut lumen in response to food ingestion. In a healthy individual 95 % of the bile acids are recycled in the enterohepatic circulation in a tightly regulated process. BAD symptoms arise due to a pathological spill-over of bile acids to the colon.

Currently, individuals with BAD are typically treated with bile acids sequestrants. However, only about 2/3 patients experience an improvement in their symptoms on this treatment. Thus, the possibility of yet another tool in the toolbox is compelling.

Statins are used by millions of patients world-wide to reduce their risk of cardiovascular morbidity and mortality and are considered safe with overall mild and benign adverse effects. Statins lower the intracellular levels of cholesterol in hepatocytes. As such, atorvastatin could potentially reduce the bile acid production in individuals with BAD leading to a reduction or normalisation of the amount of bile acids secreted to the intestinal lumen and entering the colon. Unpublished results from the investigators' group show a 43 % reduction of serum C4, a biomarker of bile acid synthesis which can also be used to diagnose BAD, in healthy, young men, who were treated with atorvastatin for 14 days (7 days of 40 mg atorvastatin once daily followed by 7 days of 80 mg atorvastatin once daily) compared to placebo treatment.

The investigators hypothesise that atorvastatin treatment lowers bile acid synthesis in patients with bile acid diarrhoea.

The current study aims to investigate whether atorvastatin treatment lowers the synthesis of bile acids, measured via the well-known bile acid synthesis marker C4, in a dose-response manner in patients with severe bile acid diarrhoea. The investigators expect the reduction of bile acid synthesis to lead to a reduction in bile acid diarrhoea symptoms since the pathophysiology of the disease is a spill-over of bile acids to the colon. Specifically, the primary endpoint is the reduction in percentage of C4 at the end of the 80 mg treatment period compared to placebo. Additionally, the investigators will investigate the effect of atorvastatin treatment in patients with severe bile acid diarrhoea on symptoms, hepatobiliary markers, metabolic markers, glycaemic control markers, stool samples and safety.

03

Conditions studied

  • Bile Acid Diarrhea
  • Bile Acid Malabsorption

Browse trials for

Keywords

  • Bile Acid Diarrhea
  • Bile Acid Malabsorption
  • Atorvastatin
  • Randomised
  • Placebo
  • 7-alpha-C4
  • Crossover
  • Double-blind
  • Investigator-initiated
  • Proof of concept
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 years or above
  • Self-identification as White
  • Confirmed moderate-severe bile acid diarrhoea with a SeHCAT test result of ≤ 10 %
  • Reported number of average daily stools ≥ 3 stools per day
  • Reported number of average daily watery (6 or 7 on the Bristol Stool Chart) stools ≥ 1 stools per day(30)
  • Informed and written consent

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to pause any of the following medications during the trial: bile acid sequestrants, morphine medication, liraglutide or anti-constipation medication (e.g., lactulose, laxoberal, magnesia)
  • Unwillingness to pause any anti-diarrhoea medication (e.g., imodium) from 3 days before initiation of each stool diary until after the respective visit
  • If regularly administering psyllium or metformin, unwillingness to agree to a stable dose of psyllium or metformin throughout the trial
  • Concomitant use of any drug in the GLP-1 receptor agonist drug class with the exception of paused liraglutide, see above
  • Concomitant use of any kind of insulin medication
  • Planned major changes in food consumption throughout the trial, including planned weight loss attempts
  • Prior use of any statin within the recent 6 months
  • Intake of larger quantities of grapefruit juice during trial participation, at the discretion of the investigator
  • History of/present hepatobiliary disorder (except for simple metabolic dysfunction-associated fatty liver disease) and/or and/or serum aspartate aminotransferase ≥ 3 times
  • Crohn's disease, ulcerative colitis, celiac disease or lactose intolerance
  • Previous intestinal resection or major intra-abdominal surgery incl. stoma (cholecystectomy and appendectomy not included)
  • Nephropathy with estimated \< 45 ml/min/1,73 m2
  • Plasma level of creatine kinase ≥ 5 times the upper limit of normal
  • A recent stroke or (within 6 months)
  • Any treatment or condition requiring acute or subacute medical or surgical intervention
  • Hypothyroidism or hyperthyroidism, if not well regulated, at the discretion of the investigator
  • Active or recent (within 6 months) malignant disease (non-melanoma skin cancer not included), at the discretion of the investigator
  • Alcohol consumption exceeding 12 units/week for women or 18 units/week for men, respectively. These thresholds are based on the limits of the European Association for the Study of the Liver
  • Drug abuse, at the discretion of the investigator
  • Fertile women not using any of the following methods for the duration of the trial until at least 5 days after end of trial: Hormonal (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormone intrauterine devices (IUD), hormonal vaginal ring or transdermal hormonal patch) associated with inhibition of ovulation, chemical (copper IUD), sterilisation, vasectomised partner with a confirmatory test, or sexual abstinence per the investigator's discretion
  • Pregnant or nursing women
  • Known or suspected to atorvastatin or any of the additives in the tablet
  • Receipt of any drug within 30 days prior to visit 0
  • Concomitant treatment with any of the following (topical administration not included): ciclosporin, telithromycin, clarithromycin, delavirdin, stiripentol, ketoconazol, voriconazol, itraconazol, posaconazol, letermovir, ritonavir, lopinavir, atazanavir, indinavir, darunavir, bocepravir, telaprevir, elbasvir/grazoprevir, ledipasvir/sofosbuvir, erythromycin, niacin, ezetimibe, fusidic acid, gemfibrozil, colchicine, digoxin, warfarin
  • Unable to speak or understand Danish or mental incapacity that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements
  • Active participation in any other clinical intervention trial (observational studies not included)
  • Other concomitant disease or treatment that according to the investigator's assessment makes the person unsuitable for study participation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the IMP except with the active ingredient (atorvastatin) omitted. Participants will be administering one tablet for two weeks followed by two tablets for two weeks. Then four weeks of washout before entering the atorvastatin arm (crossover).

    Drug: Placebo

  • Experimental
    Atorvastatin

    40 mg Atorvastatin tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the placebo tablets except containing the active ingredient (atorvastatin). Participants will be administering one tablet for two weeks followed by two tablets for two weeks (80 mg atorvastatin). Then four weeks of washout before entering the placebo arm (crossover).

    Drug: Atorvastatin

Interventions

  • Participants will be orally administering one tablet daily of 40 mg Atorvastatin for two weeks followed by two tablets daily for two weeks (totalling 80 mg daily).

  • DrugPlacebo

    Placebo tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the IMP except with the active ingredient (atorvastatin) omitted. Participants will be orally administering one tablet daily for two weeks followed by two tablets daily for two weeks.

06

What researchers measure

Primary outcomes

  1. Reduction in bile acid synthesis measured via 7alpha-Hydroxy-4-cholesten-3-on (C4)

    Ratio of geometric mean concentration of 7alpha-Hydroxy-4-cholesten-3-on (C4) at the end of the 80 mg atorvastatin treatment period compared to the end of the placebo treatment period.

    Time frame: The end of week 4 and the end of week 12.

Secondary outcomes

  1. Reduction in bile acid synthesis measured via C4

    Difference in mean concentration of 7alpha-Hydroxy-4-cholesten-3-on (C4) in μg/L at the end of the 80 mg atorvastatin treatment period compared to the end of the placebo treatment period.

    Time frame: The end of week 4 and the end of week 12.

  2. Reduction in BAD symptoms measured via a stool diary.

    Difference in mean daily stools during the last week of the 80 mg atorvastatin treatment period compared to the last week of the placebo treatment period as assessed by a 7-day stool diary

    Time frame: Week 4 and week 12.

  3. A reduction in BAD symptoms measured via a stool diary.

    Difference in mean daily watery stools during the last week of the 80 mg atorvastatin treatment period compared to the last week of the placebo treatment period as assessed by the total watery (6 or 7 on the Bristol Stool Chart) stools in a 7-day stool diary

    Time frame: Week 4 and week 12.

  4. Symptom severity measured via IBS-SSS

    Difference in symptom severity measured via a danish translation of the validated questionnaire Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS). The answers are on a scale of 0-500, where a higher score indicates worse symptoms.

    Time frame: The end of week 4 and the end of week 12.

  5. Reduction in bile acid synthesis measured via C4.

    Proportion of patients with a reduction of 7alpha-Hydroxy-4-cholesten-3-on (C4) below 31 μg/L (%)

    Time frame: The end of week 4 and the end of week 12.

  6. Reduction in bile acid synthesis measured via C4

    Proportion of patients with a reduction of 7alpha-Hydroxy-4-cholesten-3-on (C4) below 46 μg/L (%)

    Time frame: The end of week 4 and the end of week 12.

  7. Bile acid metabolism measured via FGF-19

    Fibroblast growth factor 19 (FGF-19) (pg/mL)

    Time frame: The end of week 4 and the end of week 12.

  8. Bile acid metabolism measured via blood levels of total bile acids

    Blood levels of total bile acids (μmol/L)

    Time frame: The end of week 4 and the end of week 12.

  9. Cholesterol metabolism

    Total cholesterol (mmol/L)

    Time frame: The end of week 4 and the end of week 12.

  10. Cholesterol metabolism

    Low-density lipoprotein (LDL) cholesterol (mmol/L)

    Time frame: The end of week 4 and the end of week 12.

  11. Bile acid levels measured in stool samples

    Stool sample levels of total bile acids (μmol/g)

    Time frame: The end of week 4 and the end of week 12.

07

Study locations

1 site
  • Center for Clinical Metabolic Research, Gentofte Hospital
    Hellerup, 2900, Denmark
08

References and documents

Publications

  • Lynggaard MB, Olsen SS, Forman JL, Karhus ML, Gluud LL, Lund AB, Ellegaard AM. BASTA trial: protocol for a randomised, double-blind, placebo-controlled, crossover trial investigating the effects of atorvastatin on bile acid diarrhoea. BMJ Open. 2026 Jul 28;16(7):e119827. doi: 10.1136/bmjopen-2026-119827. PubMed 42521312 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Oct 2026, 12 months.

Of 32 non-industry phase 4 interventional studies under Diarrhea, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 12 months is below that.

Counting every sponsor, half of 37 studies reached it within 32 months; a quarter within 14 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 27, 2025
StartActual
Oct 15, 2025
Primary completionActual
Oct 27, 2026was Dec 2026
CompletionActual
Oct 27, 2026was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Dec 2026→Oct 27, 2026 (actual)
Oct 30, 2026
Study completion
Dec 2026→Oct 27, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Dec 2026→Oct 27, 2026 (now actual)
    Study completion Dec 2026→Oct 27, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07042165
Lead sponsor
Asger Lund, MD
Collaborators
Fonden til Lægevidenskabens Fremme, Prosektor Axel Søeborg Ohlsens Mindelegat, Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat, Aase and Ejnar Danielsens Foundation
Responsible party
Asger Lund, MD (MD, PhD, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Jun 27, 2025
Start date
Oct 15, 2025
Primary completion
Oct 27, 2026
Completion
Oct 27, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion